
    
      The primary endpoint was response rate according to International Uniform Criteria; secondary
      endpoints were: i) time to progression (TTP), progression free survival (PFS, and overall
      survival (OS); ii) percentage of eligible PPCL patients able to mobilize and collect
      peripheral blood stem cells after LD treatment; iii) percentage of eligible PPCL patients
      able to undergo autologous or allogeneic stem cells transplantation after LD treatment; iv)
      serious/severe adverse event (SAEs) rate.
    
  